Last $2.05 USD
Change Today -0.05 / -2.38%
Volume 2.5M
ATRS On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/14/13 - $5.15
52 Week Low
07/25/14 - $2.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Medi-Jet technology to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, the needle-free auto injectors to deliver human growth hormone treatment to children without the use of a needle. Its transdermal products comprise Gelnique3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company is also developing OTREXUP for the treatment poly-articular-course juvenile RA and psoriasis; Vibex QS T for testosterone replacement therapy for men suffering from symptomatic testosterone deficiency; Vibex auto injectors; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Daewoong Pharmaceuticals; Meda Pharmaceuticals; Pfizer Inc; Population Council; and LEO Pharma. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

60 Employees
Last Reported Date: 03/13/14
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2013.

antares pharma inc (ATRS) Key Developments

Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma Inc. announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot(R) Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males. Patients enrolled in this study must have a documented diagnosis of hypogonadism, or testosterone deficiency defined as having testosterone levels below 300 ng/dL. The study will include a screening phase, a treatment titration and efficacy phase and an extended treatment phase. Approximately 150 patients will be enrolled in this study. Patients meeting all eligibility criteria will be assigned to receive a starting dose of QS T once weekly for six weeks. Adjustments to dose may be made at week seven based upon the week six pre-dose blood level. The efficacy of QS T and dose adjustment to regulate testosterone levels will be evaluated after 12 weeks of treatment. Upon completion of this phase, patients may remain on their optimized QS T dose and will be followed for an additional 40 weeks. Approximately 100 patients will be needed to complete collection of 26 weeks of safety data, and approximately 50 patients will be needed to complete collection of 52 weeks of safety data.

Antares Pharma Inc. Appoints Eamonn Hobbs as its New President and Chief Executive Officer

Antares Pharma Inc. has named Eamonn Hobbs as its new president and chief executive officer. Hobbs, 55, previously worked for two medical device manufacturers in the Albany, New York area. Most recently, he was president and CEO of Delcath Systems Inc. Delcath dismissed Hobbs in Sept. 2013 as the company faced delays in gaining federal approval to sell its product, a chemotherapy system. Before that, Hobbs became well known in the region as co-founder and CEO of AngioDynamics Inc. Hobbs is replacing Paul Wotton as president and CEO of the company.

Antares Pharma Announces Executive Changes

Antares Pharma Inc. announced the resignation of Paul K. Wotton, Ph.D. who informed the Company's Board of Directors that he will assume the position of chief executive officer of a development stage biotechnology company. Dr. Wotton also has resigned from the Antares Board of Directors. The company also announced the appointment of Eamonn P. Hobbs to the position of President and Chief Executive Officer of the company effective immediately. Mr. Hobbs joined the Antares Board of Directors in August 2009 and has over 30 years of experience in the pharmaceutical, medical device, and combination products industry, including the medical specialty fields of radiology, vascular surgery, interventional cardiology, oncology and gastroenterology. Mr. Hobbs was previously the President and Chief Executive Officer of Delcath Systems Inc.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $2.05 USD -0.05

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerus Corp $3.64 USD -0.13
Cytori Therapeutics Inc $2.12 USD -0.04
Pluristem Therapeutics Inc $2.90 USD 0.00
SurModics Inc $19.56 USD -0.19
Uroplasty Inc $2.54 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at